Examining Value Assessment Frameworks, Healthcare Economic Information, and more at ISPOR 2018 Baltimore
May 1, 2018
Xcenda's global HEOR experts join more than 4,200 attendees from around the world at ISPOR 2018 in Baltimore, Maryland. Timely topics such as healthcare economic information (HCEI) and value assessment frameworks will be our focus. Meet us at booth #801 to meet our team and learn more.
2018 Presentation Highlights
Wednesday, May 23 | 8:30 AM - 9:30 AM ET
ISSUE PANEL: Value Assessment Frameworks in an Era of Personalized Medicine: Shared Objectives or Irreconcilable Differences?
By identifying which medical treatments and procedures will work best for each patient, personalized medicine improves efficiency at both the individual and health system levels. In an environment where the US has paid increasing attention to health care costs, VAFs aim to systematically quantify which treatments provide the most benefit for patients and the health system at a reasonable cost. Indeed, the two share many objectives related to improving health outcomes. Nevertheless, the current methodologies of VAFs may not sufficiently capture the value of personalized medicine, focusing instead on population health, thereby overlooking efficiencies in patient-level health care and potentially under-valuing innovative therapies. This panel aims to expose and debate the challenges of valuing personalized medicines in the current VAF environment and identify areas of consensus on which newer methodologies can be built.
Podium and Poster Presentations
Podium Presentation | Wednesday, May 23 | 8:30 AM - 9:30 AM
- Budget Impact Analysis with Simultaneous Multiple Market Entrants: Static Versus Dynamic Baseline Market
Authors: Ken O’Day, PhD, MPA; Kellie Meyer, PharmD, MPH
Poster Session I | Monday, May 21 | 8:30 AM - 2:00 PM
- Assessing Drug Price Changes Over 1 Year and Their Influence on Budget Impact
Authors: Dylan Mezzio, PharmD, MS; Duncan Brown, PhD
Poster Session II | Monday, May 21 | 3:30 PM - 7:30 PM
- Projected Savings in Direct and Indirect Costs Due to Reduced Diabetes Prevalence With Vegetarian Diets
Author: Duygu Bozkaya, MSc, MBA
- Characterization of Patient Activation, Clinical Assessments, and Patient-reported Outcomes in T2DM Patients
Authors: Kim McLeod, MPH; Apryl Quillen, MS; Beni Turner, BS
Poster Session III | Tuesday, May 22 | 8:30 AM - 2:00 PM
- The Impact of Legislative Changes and Regulatory Guidance on Proactive Dissemination of Healthcare Economic Information: Payers’ Experiences Pre and Post Product Approval
Authors: Amy Duhig, PhD; Jay Jackson, PharmD, MPH; Stew Kaufman, MBA; Janet Hughes; Matt Sarnes, PharmD; Ena Begovic
Poster Session IV | Tuesday, May 22 | 3:30 PM - 7:30 PM
- Rifaximin and Eluxadoline Utilization for Irritable Bowel Syndrome With Diarrhea (IBS-D) in the United States and Budget Impact Analysis of Switching From Eluxadoline to Rifaximin
Authors: Duygu Bozkaya, MSc, MBA; Lisa Bloudek, PharmD, MS
- Epidemiology of Hyperhidrosis in the United States: a Systematic Literature Review
Authors: Lisa Bloudek, PharmD, MS
- 2018 Update of Health Technology Assessment Decisions Across the Globe: a Focus on Oncology
Authors: Ryan Clark, PharmD, MBA, MS; Kimberly Gittings, PharmD; Chelsey Campbell, PharmD, MBA; Kellie Meyer, PharmD, MPH
- Utilization and Impact of Value Assessment Frameworks on Payer Decisions Regarding Chimeric Antigen Receptor T-cell (CAR-T) Therapies
Authors: Victor Nguyen, PharmD; Anuja Kanaskar, PharmD; Kristen Miggliaccio-Walle, BS; Kasia Shields, PharmD, MBA, BCOP, BCPS
- Development of a Conceptual Model and Review of Patient-and Observer-reported Outcome Measures in Atopic Dermatitis
Authors: Cynthiya Ruban,PhD; Somali Misra Burgess, PhD
Poster Session V | Wednesday, May 23 | 8:30 AM - 2:00 PM
- Comparison of Adherence, Persistence, and Bleed-related Event Rates in Patients Diagnosed With Immune Thrombocytopenia and Treated With Thrombopoietin Receptor Agonists
Authors: Dana Stafkey-Mailey, PharmD, PhD; Tasneem Lokhandwala, MS, PhD
- The Budget Impact of Deflazacort for the Treatment of Duchenne Muscular Dystropy
Authors: Rashad Carlton, PharmD, MSPH; Tim Regan, BPharm, RPh, CPh
Manufacturers: We want to hear from you...